Form 4: Tenaya Therapeutics CEO Executes Tax-Related Stock Sale

Tenaya Therapeutics CEO Faraz Ali sold 3,390 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Summary

• CEO Faraz Ali sold 3,390 shares of Tenaya Therapeutics (TNYA) common stock on May 18, 2026.
• The shares were sold at an average price of $0.7934 per share.
• The transaction was executed to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs) awarded on February 6, 2025.
• Following the transaction, the CEO maintains beneficial ownership of 440,014 shares, which includes 321,581 shares underlying unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a strategic divestment.

Positives

• The sale was non-discretionary, specifically executed to satisfy tax obligations rather than reflecting a change in sentiment regarding company prospects.

Negatives

• The transaction reflects a reduction in direct share holdings, albeit for tax purposes.

Risks

• The company's stock price is currently trading at a low valuation ($0.7934 per share), which may indicate market concerns regarding the company's clinical pipeline or cash runway.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that tax-related sell-to-cover transactions are standard practice for biotech executives and do not typically signal a lack of confidence in the issuer's long-term clinical development strategy.

Comparison to Industry Standards

• The use of sell-to-cover transactions is a standard corporate governance practice for executives in the biotechnology sector to manage tax liabilities associated with equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the sale was mandatory for tax purposes and represents a small fraction of the CEO's total holdings.

Next Steps

• Future vesting of remaining 321,581 restricted stock units.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Insider Trading, Form 4, Biotech, Executive Compensation